"Corbevax will be considered as a precaution dose after completion of 6 months or 26 weeks from the date of administration of the second do...

The National Technical Advisory Group on Immunisation (NTAGI) which reviewed the data of Corbevax earlier had found significant antibody re...

The COVID-19 Working Group of the National Technical Advisory Group on Immunisation (NTAGI) made the recommendation in its 48th meeting hel...

The WHO website states that the rolling data submission has begun on June 10 and the decision date on EUL is yet to be confirmed. The compa...

The experts will review its data for its use as a standalone vaccine and will also weigh its benefits as a booster shot and take a decision...

"We will review the data of Corbevax in our next meeting slated to happen this month and evaluate if mix and match of vaccines can be allow...

India's drug regulator on Saturday granted approval to Hyderabad-based Biological E's Covid-19 vaccine Corbevax to be allowed as a booster ...

The vaccine can be administered after 6 months of administration of primary vaccination (two doses) of Covaxin or Covishield vaccines for r...

The Drugs Controller General Of India (DCGI) had already approved Corbevax, India's first indigenously developed RBD protein subunit vaccin...

"It is necessary to quickly initiate the process of recognition of the Corbevax vaccine and its certificate by other countries while Biolog...

COVID-19 vaccination of children between 12-14 years will begin from March 16 and only Corbevax vaccine would be used for the beneficiaries...

The lawmakers urged the President to use the two vaccines which are a result of India-US collaborations for the global good and to end vacc...

The company had started manufacturing in December and is expected to supply 50 million doses of the vaccine to the government this month.

Booster doses will become available in India from January 10. The prioritisation and sequence of administration would be based on completin...

The recommendations have been sent to the Drug Controller General of India (DCGI), which will soon decide on their approval, people in the ...

Currently, phase 2/3 clinical trials of the second indigenously developed Corbevax, an RBD protein sub-unit vaccine to be administered in a...

The approval for conducting phase III comparator safety and immunogenicity trial in adults came after the SEC's review of Phase I and II cl...